These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 23045585)

  • 21. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review.
    ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Meijer CJ
    J Pathol; 2003 May; 200(1):4-15. PubMed ID: 12692835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma.
    Zamkoff KW; Matulis MD; Mehta AC; Beaty MW; Hutchison RE; Gentile TC
    Bone Marrow Transplant; 2004 Mar; 33(6):635-8. PubMed ID: 15004538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
    Eyre TA; Khan D; Hall GW; Collins GP
    Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study.
    Morel A; Brière J; Lamant L; Loschi M; Haioun C; Delarue R; Tournilhac O; Bachy E; Sonet A; Amorim S; Laurent C; Gaulard P; Tilly H; Sibon D
    Eur J Cancer; 2017 Sep; 83():146-153. PubMed ID: 28735072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
    Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
    J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
    Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
    Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extra copies of ALK gene locus is a recurrent genetic aberration and favorable prognostic factor in both ALK-positive and ALK-negative anaplastic large cell lymphomas.
    Yu R; Chen G; Zhou C; Gao Z; Shi Y; Shi Y; Zhou X; Xie J; Liu H; Gong L
    Leuk Res; 2012 Sep; 36(9):1141-6. PubMed ID: 22726922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.
    Casasnovas RO; Mounier N; Brice P; Divine M; Morschhauser F; Gabarre J; Blay JY; Voillat L; Lederlin P; Stamatoullas A; Bienvenu J; Guiguet M; Intrator L; Grandjean M; Brière J; Ferme C; Salles G;
    J Clin Oncol; 2007 May; 25(13):1732-40. PubMed ID: 17389336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma.
    Schlette EJ; Medeiros LJ; Goy A; Lai R; Rassidakis GZ
    J Clin Oncol; 2004 May; 22(9):1682-8. PubMed ID: 15117990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte.
    Diviné M; Lepage E; Brière J; Pautier P; Dupriez B; Lederlin P; Mineur P; Tilly H; Blanc M; Audhuy B; Herbrecht R; Coiffier B; Reyes F
    J Clin Oncol; 1996 Jan; 14(1):240-8. PubMed ID: 8558204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.
    Cederleuf H; Bjerregård Pedersen M; Jerkeman M; Relander T; d'Amore F; Ellin F
    Br J Haematol; 2017 Sep; 178(5):739-746. PubMed ID: 28485010
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical analysis of primary systemic anaplastic large cell lymphoma: a report of 57 cases.
    Wang FH; Li YH; Zeng J; Rao HL; Xia ZJ; Sun XF; Huang HQ; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2009 Jan; 28(1):49-53. PubMed ID: 19448428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of therapy of different variants of anaplastic large T-cell lymphomas].
    Vinogradova IuE; Lutsenko IN; Kaplanskaia IB; Vorob'ev IA; Samoĭlova RS; Gorgidze LA; Ryzhikova NA; Valiev TT; Giliazitdinova EA; Dzhulakian UL; Egorova EK; Zvonkov EE; Krasil'nikova BB; Magomedova AU; Margolin OV; Mar'in DS; Kremenetskaia AM; Kravchenko SK; Vorob'ev AI
    Ter Arkh; 2008; 80(7):33-7. PubMed ID: 18763592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas.
    Salaverria I; Beà S; Lopez-Guillermo A; Lespinet V; Pinyol M; Burkhardt B; Lamant L; Zettl A; Horsman D; Gascoyne R; Ott G; Siebert R; Delsol G; Campo E
    Br J Haematol; 2008 Mar; 140(5):516-26. PubMed ID: 18275429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
    Escalón MP; Liu NS; Yang Y; Hess M; Walker PL; Smith TL; Dang NH
    Cancer; 2005 May; 103(10):2091-8. PubMed ID: 15816054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte.
    Mounier N; Morel P; Haioun C; Coiffier B; Tilly H; Chatelain C; Lederlin P; Thyss A; Herbrecht R; Gisselbrecht C; Lepage E
    Cancer; 1998 May; 82(10):1952-62. PubMed ID: 9587130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte.
    Decaudin D; Lepage E; Brousse N; Brice P; Harousseau JL; Belhadj K; Tilly H; Michaux L; Chèze S; Coiffier B; Solal-Céligny P
    J Clin Oncol; 1999 Aug; 17(8):2499-505. PubMed ID: 10561315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis.
    Mussolin L; Damm-Welk C; Pillon M; Zimmermann M; Franceschetto G; Pulford K; Reiter A; Rosolen A; Woessmann W
    Leukemia; 2013 Feb; 27(2):416-22. PubMed ID: 22907048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
    Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F;
    Ann Oncol; 2004 Dec; 15(12):1790-7. PubMed ID: 15550584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma.
    Pedersen MB; Danielsen AV; Hamilton-Dutoit SJ; Bendix K; Nørgaard P; Møller MB; Steiniche T; d'Amore F
    Histopathology; 2014 Oct; 65(4):490-500. PubMed ID: 24592992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.